MAINSTAY-MEDICAL
Mainstay Medical Holdings plc announced today that the National Institute for Health and Care Excellence (NICE), a public body of the Department of Health that carries out evidence-based health technology assessments by independent committees, has issued a recommendation that ReActiv8® Restorative Neurostimulation™ can be used in the National Health Service in the U.K., with special arrangements for clinical governance, consent, and audit or research. ReActiv8 is currently the only technology offering restorative neurostimulation to the NHS for refractory mechanical chronic low back pain (CLBP).
“U.K. physicians have some of the most extensive experience with ReActiv8 globally. We are thankful to NICE for recognizing this experience, as well as the substantial body of global evidence we have developed in support of the efficacy and safety of this ground-breaking therapy, “ said Jason Hannon, CEO of Mainstay Medical. “This new guidance will enable patients to have greater access to the therapy when previous treatment options have not proven successful. We look forward to supporting physicians across the U.K. going forward and to continued improvement in patient outcomes.”
“Historically, mechanical CLBP pain therapies were aimed at only managing the symptoms, which is the pain associated with this pathology,” said Dr. Ganesan Baranidharan, Consultant in Anaesthesia and Pain Medicine, Leeds Teaching Hospitals NHS Trust. “ReActiv8 is the only therapy available I am aware of where patients with many years of CLBP actually reverse and effectively rehabilitate their condition durably over a long period of time. ReActiv8 targets the cause of mechanical CLBP, not just the symptoms. The new NICE guidance is a major victory for patients and clinicians, which further confirms the positive patient outcomes we have seen to date. This new guidance will allow more patients to gain access to ReActiv8 within the U.K. and further afield.”
The NICE publication can be found here: Evidence | Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain | Guidance | NICE
About ReActiv8®
ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. Multifidus muscle dysfunction may be evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy, and who are not candidates for spine surgery. ReActiv8 has received regulatory approval in several geographic areas, and is commercially available in the European Economic Area, Australia, the UK, and the US.
About Mainstay Medical
Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation™ system, ReActiv8®, for people with disabling mechanical CLBP. Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.
Further information can be found at www.mainstaymedical.com.
Forward-Looking Statements
All statements in this announcement other than statements of historical fact are, or may be deemed to be, forward-looking statements. These forward-looking statements may include, without limitation, statements regarding the company’s intentions, beliefs or current expectations concerning, among other things, the company’s commercial efforts and performance, including the use of the ReActiv8 therapy by physicians and patients in the U.K. and elsewhere, and the company’s financial position, financing strategies, product design and development, regulatory applications and approvals, and reimbursement arrangements.
Forward-looking statements involve risk and uncertainty and are not guarantees of future performance. Actual results may differ materially from those described in, or suggested by, the forward-looking statements. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements herein, including, without limitation, the risks and uncertainties included in the company’s Annual Report for the year ended 31 December 2021, which should be read in conjunction with the company’s public disclosures (available on the company’s website (www.mainstaymedical.com). The forward-looking statements herein speak only as of the date of this announcement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005133/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Hosts Inclusion International 18th World Congress 2025 ‘We Are Inclusion’ for the First Time, With 600 Participants From 74 Countries19.9.2025 19:07:00 CEST | Press release
Sharjah hosted the 18th edition of the World Congress 2025 “We Are Inclusion” for the first time in the Middle East and North Africa, under the patronage and in the presence of His Highness Sheikh Dr. Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919788186/en/ Honorary Lifetime Membership certificate awarded to Sheikha Jameela bint Mohammed Al Qasimi by Inclusion International (Photo: AETOSWire) The event was held from September 15 - 17 at Expo Centre Sharjah, and organised by the Sharjah City for Humanitarian Services (SCHS) and Inclusion International, with support from the strategic partnership of the Sharjah Government Media Bureau. The congress brought together 152 speakers, including self-advocates, families, experts, and policymakers from 160 organisations across 74 countries, featuring 59 sessions, with 600 participants. During the event,
Estithmar Holding’s Listing on FTSE Mid Cap Index is Effective19.9.2025 17:02:00 CEST | Press release
As of September 18, The Qatar based Estithmar Holding Q.P.S.C. has been included in the FTSE Mid Cap Index following the September 2025 FTSE Global Equity Index Series (GEIS) Semi-Annual Review. Changes will be effective as of COB 18 Sep 2025.This inclusion reflects Estithmar Holding’s growing footprint in both regional and global markets, further strengthening its visibility among international investors and underlining its position as one of the region’s leading diversified public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919701856/en/ Estithmar Holding’s Listing on FTSE Mid Cap Index is Effective (Photo: AETOSWire) The FTSE Russell index is widely tracked by international institutional investors and asset managers, and Estithmar Holding’s inclusion is expected to broaden its investor base globally, resulting in significant investment flows. The move also contributes to improving the financial attractive
LambdaTest Leads with First-to-Market Support for iPhone 17 Series on Real Devices19.9.2025 17:00:00 CEST | Press release
With iPhone 17 Series Testing Now Live, LambdaTest Boosts Developer Productivity and Streamlines Mobile App Testing Processes LambdaTest, the GenAI-native quality engineering platform, has announced the immediate availability of the iPhone 17 Series, including the iPhone 17, iPhone 17 Pro, iPhone 17 Pro Max, and the iPhone Air, on its Real Devices Platform, just hours after the official launch of Apple’s latest lineup. The addition of the iPhone 17 series further enhances LambdaTest’s already robust real device cloud, which spans thousands of iOS and Android devices. This expansion enables comprehensive cross-device and cross-OS testing at scale, ensuring developers can thoroughly test their mobile apps across a diverse range of real-world environments. “Once again, we’re the first to offer the latest iPhone models for real device testing,” said Asad Khan, CEO and Co-Founder of LambdaTest. “This launch is a testament to our commitment to providing the most up-to-date testing solutions
World-renowned Blood Transfusion Congress to Be Held in Yokohama in 202819.9.2025 17:00:00 CEST | Press release
The 2028 International Congress of the International Society of Blood Transfusion (ISBT 2028) will be held in Yokohama from June 4 to June 8, 2028. Organized collaboratively by ISBT and The Japan Society of Transfusion Medicine and Cell Therapy (JSTMCT), this marks the event’s return to Japan after 19 years, following three previous international (1960, 1996) and regional congresses (2009) held in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919907189/en/ YOKOHAMA JAPAN'S FIRST PORT OF CALL Working in partnership with the City of Yokohama and the Japan National Tourism Organization (JNTO), the Yokohama City Visitors Bureau (YCVB) and PACIFICO Yokohama supported JSTMCT’s successful bid to host ISBT 2028. The decision is testament to Japan’s advanced research capabilities, Yokohama’s convenient access and robust support infrastructure, and PACIFICO Yokohama’s outstanding reputation for hosting international c
OCP Announces Date of Second Quarter and First Half 2025 Earnings19.9.2025 14:30:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2025 results on Friday, September 26, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 11:00 a.m. EDT, 4:00 p.m. Morocco and London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2025 results at 12:00 p.m. EDT, 5:00 p.m. Morocco and London time (GMT+1) on Friday, September 26, 2025, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom